• Explore /
  • Poster
  • / Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.

Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.

Abstract Poster

Authors

Arjun Balar

Arjun Vasant Balar

NYU Langone Health Perlmutter Cancer Center, New York, NY

Arjun Vasant Balar , Nicholas D. James , Shahrokh F. Shariat , Neal D. Shore , Michiel Simon Van Der Heijden , Andrew James Weickhardt , Xiao Fang , James Luke Godwin , Ekta Kapadia , Jeff M. Michalski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT04241185

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS5093)

DOI

10.1200/JCO.2020.38.15_suppl.TPS5093

Abstract #

TPS5093

Poster Bd #

162

Abstract Disclosures

Similar Posters

First Author: Andrew James Weickhardt

First Author: Shilpa Gupta

First Author: Arlene O. Siefker-Radtke

First Author: Minas P. Economides